These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 17325588

  • 21. [Effects of chelation therapy with succimer in young rabbits of moderate lead poisoning].
    Yu GY, Yan CH, Yu XG, Zuo Y, Zou XY, Xu J, Wu SH, Shen XM.
    Zhonghua Yu Fang Yi Xue Za Zhi; 2009 Jan; 43(1):8-13. PubMed ID: 19534872
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model.
    Madsen MT, Bushnell DL, Juweid ME, Menda Y, O'Dorisio MS, O'Dorisio T, Besse IM.
    J Nucl Med; 2006 Apr; 47(4):660-7. PubMed ID: 16595501
    [Abstract] [Full Text] [Related]

  • 24. Succimer treatment and calcium supplementation reduce tissue lead in suckling rats.
    Marija Varnai V, Piasek M, Blanusa M, Matek Sarić M, Juresa D, Kostial K.
    J Appl Toxicol; 2004 Apr; 24(2):123-8. PubMed ID: 15052607
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Biodistribution and internal dosimetry of the 188Re-labelled humanized monoclonal antibody anti-epidemal growth factor receptor, nimotuzumab, in the locoregional treatment of malignant gliomas.
    Torres LA, Coca MA, Batista JF, Casaco A, Lopez G, García I, Perera A, Peña Y, Hernández A, Sanchez Y, Romero S, Leyva R, Prats A, Fernandez R.
    Nucl Med Commun; 2008 Jan; 29(1):66-75. PubMed ID: 18049099
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Factors influencing the efficiency of chelation therapy.
    Kostial K, Kargacin B, Arezina R, Landeka M, Simonović I.
    J Hyg Epidemiol Microbiol Immunol; 1991 Jan; 35(4):337-50. PubMed ID: 1804865
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Long-term toxicity of [(177)Lu-DOTA (0),Tyr (3)]octreotate in rats.
    Rolleman EJ, Krenning EP, Bernard BF, de Visser M, Bijster M, Visser TJ, Vermeij M, Lindemans J, de Jong M.
    Eur J Nucl Med Mol Imaging; 2007 Feb; 34(2):219-27. PubMed ID: 17021812
    [Abstract] [Full Text] [Related]

  • 36. Ustur whole body case 0269: demonstrating effectiveness of i.v. CA-DTPA for Pu.
    James AC, Sasser LB, Stuit DB, Glover SE, Carbaugh EH.
    Radiat Prot Dosimetry; 2007 Feb; 127(1-4):449-55. PubMed ID: 18227077
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.